FindTrial
Sign In

To estimate the water loss through the epidermis and a scale called Eczema area and severity index to compare the efficacy of two topical medications called crisaborole 2% and tacrolimus 0.1% in patients with mild to moderate atopic dermatitis.

Estimation of transepidermal water loss and eczema area and severity index in patients with mild to moderate atopic dermatitis receiving topical crisaborole 2 % vs topical tacrolimus 0.1% - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/067254
Enrollment
90
Registered
2024-05-13
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Dr Aisha Salim
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with AD willing to participate and those with age 16 and more with the diagnosis of mild to moderate Atopic dermatitis on the basis of Hannifin and Rajka criteria.

Exclusion criteria

Exclusion criteria: 1. Patient on topical and systemic corticosteroid, Immunosuppressants , UVA and UVB therapy . 2. Patients with atopic dermatitis having other skin diseases. 3. Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
To evaluate TEWL in adult patients with mild to moderate atopic dermatitis receiving topical crisaborole 2% and topical tacrolimus 0.1% To evaluate the EASI score in adult patients with mild to moderate atopic dermatitis receiving topical crisaborole 2% and topical tacrolimus 0.1%Timepoint: Baseline (day 0), week 2 and week 4.—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Aisha salim

Father Muller Medical College Hospital

rochelle@fathermuller.in9739315324

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026